Tag Archives: Phil Nadeau

Cowen & Co. Sticks to Their Hold Rating for PDL BioPharma (PDLI)

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on PDL BioPharma (PDLI – Research Report) today and set a price target of $3. The company’s shares opened today at $2.46. According to TipRanks.com, Nadeau is a 5-star analyst

Regeneron (REGN) Receives a Hold from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Regeneron (REGN – Research Report), with a price target of $385. The company’s shares opened today at $357.61. According to TipRanks.com, Nadeau is a

Cowen & Co. Thinks Dynavax’s Stock is Going to Recover

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Dynavax (DVAX – Research Report), with a price target of $30. The company’s shares closed yesterday at $11.12, close to its 52-week low of

Cowen & Co. Thinks Epizyme’s Stock is Going to Recover

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $8.30, close to its 52-week low of $7.61. According to TipRanks.com, Nadeau is a 5-star analyst with an average

Acorda Therapeutics (ACOR) Receives a Buy from Cowen & Co.

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Acorda Therapeutics (NASDAQ: ACOR) today and set a price target of $30. The company’s shares opened today at $19.11. According to TipRanks.com, Nadeau is a 4-star analyst with an

Cowen & Co. Thinks Celgene’s Stock is Going to Recover

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Celgene (NASDAQ: CELG) today and set a price target of $150. The company’s shares opened today at $75.55, close to its 52-week low of $72.30. According to TipRanks.com, Nadeau